Developmental Adipokines and Maternal Obesity Interactions

R.G. Ahmed

Division of Anatomy and Embryology, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt

Email: ahmedragab08@gmail.com Tel. number: 002-010-9147-1828

Abstract

Adipokines are involved in the developmental programming during fetal development and early life, and might contribute to pregnancy complications. Maternal obesity has an impact on intrauterine fetal life that extends to abnormal changes in the adipose tissue and metabolic disorders in the newborns and even adulthood. This overview discusses the potential importance of adipokines during gestational diabetes mellitus (GDM) and in fetal metabolic programming. Various adipokines secreted from fat tissue as the key players in reprogramming maternal physiology to achieve an insulin-resistant state during pregnancy, especially when complicated by GDM. Indeed, this review hypothesized that the disturbance in adipokines may be associated with GDM in pregnant obese women or animals. This may influence, generally, on the health of the embryos, newborns and adulthood depending on proinflammatory markers. Finally, the obesity of mothers and disturbance in adipokines prior to pregnancy are a significant risk factor for the disturbed development of the pregnancy and the child, and develop metabolic syndrome. However, there are obvious species differences between pregnant women and animal models. Thus, maintaining normoglycaemia and adipokines levels during pregnancy may play an important role in a healthy life for the newborns.

Key words: Adipokines; obesity; mothers; development; offspring.
I- Introduction

Obesity is powerfully linked with changes in the physiological function of adipose tissue, leading to insulin resistance, chronic inflammation, and altered secretion of adipokines (Blajnić et al., 2014; Prior et al., 2014; Ramirez et al., 2014). Indeed, adipose tissue dysfunction might play a critical role in the different obesity linked diseases including inflammation, insulin resistance and cancer. White adipose tissue (WAT) is a complex and metabolically active organ, with a relevant vital role in regulating whole-body metabolism (Houde et al., 2013). WAT is the largest energy storage organ, having an essential lipid storing capacity in periods when energy input exceeds energy expenditure and with a lipolytic function during energy deprivation (Jenum et al., 2013; Loy and Hamid Jan, 2014). In addition to its primary role as a fuel reservoir, WAT has been confirmed as a principal endocrine organ, since the tissue synthesizes and secretes an array of sex steroids, and bioactive peptides termed ‘adipokines’, involved in the physiological regulation of fat storage, energy metabolism, food intake, insulin sensitivity, and immune function among others (Khalyfa et al., 2013). In this section, I summarized the general biological function of adipose tissue in table (1) and figure (1), and I compared between the secretion and action of potentially beneficial adipokines (leptin, adiponectin, apelin and visfatin) linking to obesity in table (2).

II- Summary about the different states of adiponectinaemia (Table 3).

III- Role of inflammation in pathogenesis of insulin resistance, obesity and cardiovascular diseases (Table 4):

Increased adipose tissue mass that is linked with obesity and cardiovascular disease has been associated with a low-grade, chronic inflammatory response that is characterized by altered production of adipokines and increased markers of inflammation, such as TNF-α and IL6 (Stupin and Arabin, 2014) or MCP-1 (Harwood Jr, 2012). Over-stimulation of inflammatory pathways in insulin-sensitive tissues provides rise to local and systemic insulin resistance (Cai et al., 2005). Markers of systemic inflammation in humans are strongly connected with insulin resistance (de Rooij et al., 2009) and predict the development of diabetes type two (T2DM) (Ahmed, 2011; Miehle et al., 2012). Infact, acute TNF-α infusion induces skeletal muscle insulin resistance in humans (Plomgaard et al., 2005), while both acute and chronic MCP-1 infusion stimulates insulin resistance in rodents (Kalupahana et al., 2012). Notably, adipose tissue cells from the stromal vascular fraction, and in particular resident macrophages, are responsible for the chronic inflammatory responses recorded in obesity (Weisberg et al., 2003). These resident macrophages vary in their properties depending on whether they are contained in lean or fat-laden adipose tissue (Harwood Jr, 2012). For example, macrophages residing in lean adipose tissue are illustrated by increased expression of anti-inflammatory cytokines, such as interleukin 10 (IL-10), explain an increased capacity for tissue repair and angiogenesis, and are frequently referred to as M2, or alternatively-activated macrophages (Lumeng et al., 2007). However, expansion of adipose tissue in obesity is linked with an increased infiltration by circulating macrophages of the M1, or classically-activated, phenotype (Coenen et al., 2007). These macrophages are characteristically recruited to sites of tissue damage and are in a pro-inflammatory state with increased expression of proinflammatory cytokines, such as TNF-α and IL6, that can exert strong paracrine effects on a variety of adipose tissue functions (Lumeng et al., 2007). The local effects of proinflammatory cytokines on adipose tissue lipolysis may contribute to the development of insulin resistance by promoting the liberate of fatty acids from adipose tissue into the circulation, which may then lead to lipid accumulation and insulin resistance in other tissues such as skeletal muscle and liver (Goossens, 2008). Furthermore, reduced adiponectin concentrations may have harmful effects on fat oxidation, since it has been demonstrated that adiponectin increases fat oxidation via activation of AMP-activated protein kinase in rat skeletal muscle and myocytes (C2C12) (Yamauchi et al., 2002). Interestingly, in humans, low adiponectin serum levels at baseline independently predict future risk to develop T2DM (Spranger et al., 2003) and coronary artery disease (Fasshauer et al., 2004) and high plasma adiponectin predicts a lower risk of future myocardial infarction (Pischon et al., 2004). We summarized the different states for adiponectinaemia in table 3. It is obvious from these studies that there are linking between insulin receptor signaling and inflammatory pathways (Hirosumi et al., 2002). Generally, the detailed of pro-inflammatory cytokines and chemokines during obesity are discussed in table 4.

V- Adipokines, maternal obesity and development (figure 3):

Gestation is a stage that results in increased adipocyte volume, and it is recognized that adipose fat depots are the net balance of synthesis and hydrolysis of triacylglycerols via lipogenesis and lipolysis (Ramos et al., 2003). Also, several adipokines such as leptin (LEP; OMIM 164160), adiponectin (ApN; OMIM 605441),
resistin (RETN; OMIM 605565) and inflammatory cytokines [tumor necrosis factor-α (TNF-α; OMIM 191160), and interleukin-6 (IL-6; OMIM 147620)], and chemokines [interleukin-8 (IL-8; OMIM 146930)] have been suggested as much stronger predictors of pregnancy-linked insulin resistance than gestational hormones, including human placental lactogen and steroids (Radaelli et al., 2003; Taylor et al., 2014). Recently, adiponectin secretion and adiponectin mRNA levels in WAT decline with the gestation progress suggesting that there are pregnancy-associated factors that reduce adiponectin levels (Catalano et al., 2006). In addition, in humans, the developing placenta expresses both leptin and its receptor, and placental resistin (Zavalza-Gómez et al., 2008). Their levels correlate with the condition of reduced insulin sensitivity often developed in the latter stages of pregnancy, thus contributing to successful development of the fetus (Cortelazzi et al., 2007). Furthermore, the human placenta has been found to express nearly all known cytokines. Increasing adiposity is associated with the secretion of proinflammatory cytokines from adipose tissue, suggesting that these cytokines may play an essential role in fuel availability during pregnancy (Lyon et al., 2003). Moreover, cytokine production is related to pathologic risk and to delivery mode itself (Malamitsi-Puchner et al., 2005).

There have been only a few papers demonstrating cytokine profiles, including many kinds of cytokines in cord blood (Takahashi et al., 2010). IL-6 is a useful marker for a systemic fetal inflammatory response (Gomez et al., 1998). Also, the levels of IL-8, MCP-1 and MIP-1b were increased in preterm birth (Matoba et al., 2009) and serum levels of IL-8 and MCP-1 in cord blood significantly associated with gestational ages (Takahashi et al., 2010). However, IL-4 and IL-13 did not cross the placenta measurable amounts (Lim et al., 2009). In previous investigations, circulating levels of leptin, adiponectin and TNF-α in the early pregnancy strongly predicted the development of GDM (Gao et al., 2008). Also, GDM elicits main variations in the expression profile of placental genes with a prominent increase in markers and mediators of inflammation (Radaelli et al., 2003).

Previous studies have reported a connection between childhood maltreatment and adulthood obesity (Midei et al., 2010). Obesity is also associated with lowered serum adiponectin levels which reflect a disturbed inflammatory state during childhood (Gustafson, 2010). Adiponectin inhibits the functions of TNF-α which associated with post-traumatic stress disorder (Gustafson, 2010) and inhibits the secretion of several other pro-inflammatory cytokines from endothelial cells (Gustafson, 2010). This can increase the childhood vulnerability to depression and permanent hyperactivity of the sympathetic nervous system, as well as a variety of conditions linked to disturbed inflammatory systems (Chamvandari et al., 2003). Based on these observations, placental-derived hormones are supposed to be a main factor in reprogramming maternal physiology to achieve an insulin-resistant state. However, more studies are essential about this issue.

VI- Future directions

- Discover the ranges of several adipokines serum levels at which obesity-related disorders are observed with high frequency. These measurements could therefore be used as a biologic marker and/or pharmacologic agent in the management of obesity, inflammatory, metabolic, and cardiovascular disorders.

- Determine the complex nature of several adipokines signaling and their specific roles during pregnancy.

VII- Conflict of Interest: There is no conflict of interest.

VIII- References

1. Ahima RS. Adipose tissue as an endocrine organ. Obesity 2006;14:242S-249S.


The role of inflammatory fibrosis...


German AJ, Ryan VH, German AC, Wood IS, Trayhurn P. Obesity, its associated disorders and the role of inflammatory adipokines in companion animals. The Veterinary J. 2010;185:4–9.


at during early pregnancy is


195 | Page  March 31, 2015


107. Stupin JH, Arabin B. Overweight and Obesity before, during and after Pregnancy


109. Overweight and Obesity before, during and after Pregnancy


IX- Legends

- Table legends:
  Table 1: Summary about the biological function of adipose tissue.
  Table 2. General action of leptin, adiponectin, apelin and visfatin linking to obesity.
  Table 3. Summary about the different states of adiponectinae.
  Table 4. Pro-inflammatory cytokines and chemokines during obesity.
- Figure legends:
Figure 1. General adipokines network.
Figure 2. Adipokines and insulin resistance interactions.
Figure 3. Adipokines, maternal obesity and development.

X- Abbreviations
ApN, adiponectin;
ApoE, apoliproprotein E;
ASP, acylation-stimulating protein;
AT, adipose tissue;
BAT, brown adipose tissue;
BBB, blood–brain barrier;
BMI, body mass index;
CETP, cholesterol ester transfer protein;
CRP, C-reactive protein;
CVD, cardiovascular disease;
ER, endoplasmic reticulum;
FABPs, fatty-acid-binding proteins;
FFA, free fatty acid;
GDM, gestational diabetes mellitus;
HMW, high molecular weight;
IGF-1, insulin like growth factor-1;
IL-6,8,10, interleukin-6,8,10;
LEP, leptin;
LPL, lipoprotein lipase;
MCP-1, monocyte chemo-attractant protein-1;
MIF, macrophage migration inhibitory factor;
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells;
NGF, nerve growth factor;
PAl-1, platelet (plasminogen) activator inhibitor-1;
RBP4, retinol binding protein-4;
RETN, resistin;
SAA, serum amyloid A;
Sc, Subcutaneous;
SVC, stromal-vascular cells;
T2DM, diabetes type two;
TGF-β, transforming growth factor-β;
TNF- β, tumor necrosis factor- β;
TNF-α, tumor necrosis factor-α;
VEGF, vascular endothelial growth factor;
WAT, White adipose tissue;
## Table 1. Summary about the biological function of adipose tissue.

<table>
<thead>
<tr>
<th>Compare face</th>
<th>Functions</th>
<th>Increase food intake (obesity)</th>
<th>Increase food expenditure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Leptin</strong></td>
<td>- Appetite and energy balance&lt;br&gt;- Adipogenesis&lt;br&gt;- Metabolic functions&lt;br&gt;- Immune modulator&lt;br&gt;- Inflammatory responses&lt;br&gt;- Secretory functions</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td><strong>ApN</strong></td>
<td>- Appetite and energy balance&lt;br&gt;- Glucose homeostasis&lt;br&gt;- Fatty acid catabolism&lt;br&gt;- Adipogenesis&lt;br&gt;- Secretory functions&lt;br&gt;- Strong anti-inflammatory function&lt;br&gt;- Promotes the phagocytosis of apoptotic cells&lt;br&gt;- A potent antiatherogenic factor&lt;br&gt;- Specific marker for insulin sensitivity and metabolic processes</td>
<td>Decrease</td>
<td>Increase</td>
</tr>
<tr>
<td><strong>Resistin</strong></td>
<td>- Insulin resistance&lt;br&gt;- Metabolic functions</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td><strong>Visfatin</strong></td>
<td>- Insulin secretion&lt;br&gt;- Specific marker for insulin sensitivity and metabolic processes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Apelin</strong></td>
<td>- Blood pressure&lt;br&gt;- Modulation of food intake.&lt;br&gt;- Specific marker for insulin sensitivity and metabolic processes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vaspin</strong></td>
<td>- Specific marker for insulin sensitivity and metabolic processes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RBP4</strong></td>
<td>- Insulin resistance&lt;br&gt;- Increases insulin resistance</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FFA</strong></td>
<td>- Insulin sensitivity and control of carbohydrate storage and oxidation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Glycerol</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cholesterol</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TNF-α</strong></td>
<td>- They are cytokines</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IL-6, -8</strong></td>
<td>- Inflammation&lt;br&gt;- Adipogenesis&lt;br&gt;- Metabolic functions&lt;br&gt;- Secretory functions</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IL-10</strong></td>
<td>- Anti-inflammatory role countering pro-inflammatory agents such as lipopolysaccharide (LPS) and TNF-α</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TNF-β</strong></td>
<td>- It is cytokine</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adipsin</strong></td>
<td>Stimulates triglyceride storage in adipocytes; activates alternate complement pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>Omentin</strong></td>
<td>Believed to enhance the actions of insulin</td>
<td>Decrease</td>
<td>Increase</td>
</tr>
<tr>
<td><strong>VEGF</strong></td>
<td>Stimulates angiogenesis (vascular proliferation) in white adipose tissue</td>
<td>Increase</td>
<td>Decrease</td>
</tr>
<tr>
<td><strong>NGF</strong></td>
<td>It is neurotrophins</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PAI-1</strong></td>
<td>Inhibits plasminogen activation; blocks fibrinolysis; Haemostatic and haemodynamic factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FABPs</strong></td>
<td>Family of carrier proteins for fatty acids and other lipophilic substances such as eicosanoids and retinoids. These proteins are thought to facilitate the transfer of fatty acids between extra- and intra-cellular membranes.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Angiotensinogen</strong></td>
<td>Haemostatic and haemodynamic factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TGF-β</strong></td>
<td>Regulates preadipocyte proliferation and differentiation and also adipocyte apoptosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MIF</strong></td>
<td>It is chemokine. Immunoregulator with paracrine actions in white adipose tissue</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MCP-1</strong></td>
<td>It is chemokine. Recruits monocytes to sites of injury and inflammation</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LPL</strong></td>
<td>Hydrolyzes triglycerides in triglyceride-rich lipoproteins allowing cellular uptake</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IGF-1</strong></td>
<td>Stimulates proliferation and differentiation of adipocytes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CETP</strong></td>
<td>Transfers cholesterol esters between lipoproteins</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ASP</strong></td>
<td>Stimulates triglyceride synthesis in white adipose tissue; antilipolytic</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ApoE</strong></td>
<td>Protein component of triglyceride-rich lipoproteins</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tissue factor</strong></td>
<td>Initiates the coagulation cascade</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SAA</strong></td>
<td>They are acute phase proteins</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CRP</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Metallothelin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Haptoglobin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Steroid hormones</strong></td>
<td>Anti-inflammatory</td>
<td></td>
<td>Change</td>
</tr>
</tbody>
</table>

Adapted from Otero et al. (2003), Kadowaki & Yamauchi (2005), Tilg and Wolf (2005), Ahima (2006), Ronti et al. (2006), Fonseca-Alaniz et al. (2007), Takemura et al. (2007), Hajer et al. (2008), Vázquez-Vela et al (2008), Zou & Shao (2008), Lagol et al. (2009), German et al. (2010), Karastergiou & Mohamed-Ali (2010), Cekmez et al. (2011) and Harwood Jr (2012). ApN, adiponectin; ApoE, apolipoprotein E; ASP, acylation-stimulating protein; CETP, cholesterol ester transfer protein; CRP, C-reactive protein; FABPs, fatty-acid-binding proteins; FFA, free fatty acid; IGF-1, insulin like growth factor-1; IL-6,8,10, interleukin-6,8,10; LPL, lipoprotein lipase; MCP-1, monocyte chemo-attractant protein-1; MIF, macrophage migration inhibitory factor; NGF, nerve growth factor; PAI-1, platelet (plasminogen) activator inhibitor-1; RBP4, retinol
binding protein-4; SAA, serum amyloid A; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; TNF- β, tumor necrosis factor- β; VEGF, vascular endothelial growth factor.

*a Secreted proteins without hormonal actions.

Table 2. General action of leptin, adiponectin, apelin and visfatin linking to obesity.

<table>
<thead>
<tr>
<th>Compare face</th>
<th>Leptin</th>
<th>Adiponectin (ApN)</th>
<th>Apelin</th>
<th>Visfatin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nature</td>
<td>It is a 16-kDa hormone produced by adipocytes and virtually undetectable in the stromal-vascular cells fraction of adipose tissue. Its expression is restricted to mature fat cells in man (Halleux et al., 2001).</td>
<td>It is a 30-kDa protein abundantly secreted by adipose tissue (Maeda et al., 1996; Scherer et al., 1995). It found in the blood stream in three forms: trimer, hexamer and high molecular weight (HMW) 12- to 18-mer ApN (Kadowaki et al., 2006).</td>
<td>It is the endogenous ligand for the orphan G-protein coupled receptor, AJP, which is the closest homolog to angiotensin II receptor (Japp et al., 2008). It is present in several tissues, in the bloodstream and adipose tissue (AT) (Cekmez et al., 2011).</td>
<td>It is as a protein involved in immune B-cell maturation (pre-B colony enhancing factor, PBEF) (Samal et al., 1994) and with insulin-like functions (Fukuhara et al., 2005). It found in visceral AT, from which the name visfatin was derived (Fukuhara et al., 2005).</td>
</tr>
<tr>
<td>Metabolic effects</td>
<td>Energy metabolism</td>
<td>Increase energy consumption in brown adipose tissue (BAT) (Pang and Narendran, 2008). Decrease energy storage in white adipose tissue (WAT) (Scarpace and Matheny, 1998).</td>
<td>Not reported</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Lipid metabolism</td>
<td>Increase Lipolysis, fatty acid oxidation (Scarpace and Matheny, 1998) and apoptosis of adipocytes (Lago et al., 2009). Decrease fatty acid synthesis (Takekoshi et al., 1999).</td>
<td>Increase fatty acid oxidation in muscle (Emilsson et al., 1997). Decrease tryglycerides in liver and lypogenesis in liver (Emilsson et al., 1997; Carbone et al., 2012).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carbohydrate metabolism</td>
<td>Increase levels of GLUT-4 in BAT, glycogen synthesis in liver, glucose uptake in BAT (Qian et al., 1998) and insulin sensitivity (Bai et</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carbohydrate metabolism</td>
<td>Increase insulin sensitivity in liver (Emilsson et al., 1997) and levels of GLUT-4 in</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| General action | - Central action:  It represents a signal to the brain (e.g., hypothalamus, cortex and limbic areas) to inhibit food intake and reduce weight (Zhang et al., 1994) because of humans and rodents lacking a functional leptin protein manifested insatiable feeding and obesity (Hajer et al., 2008). The vital action of leptin in the hypothalamus has been best described with regards to energy homeostasis and reproductive functions (Badman and Flier, 2007). Additionally to its action on the hypothalamus, leptin may also act on the cortex and limbic areas, which are regulated the cognitive and emotional feeding behavior (Faroogi et al., 2007; Rosenbaum et al., 2008). As predictable, leptin treatment successfully reversed the obesity and leptin resistance abnormalities (Ahima, 2008). Currently, leptin represents as a hormone responsible for signaling energy deficiency rather than a signal to lose weight (Badman and Flier, 2007; Kershaw and Flier, 2004).  

- Peripheral action:  It has actions in a number of peripheral tissues (e.g., cells of the pancreas, liver and immune system) (Karastergiou and Mohamed-Ali, 2010). Moreover, disruption of peripheral leptin signaling in mice caused no significant variation in energy balance or glucose homeostasis (Guo et al., 2007).  

Conversely to most adipokines, circulating ApN is negatively associated with the body mass index (BMI) (Arita et al., 1999; Brichard et al., 2003) and decreased in obese subjects, in type 2 diabetes or cardiovascular disease (CVD) (Ouchi and Walsh, 2007). This sub-regulation may involve the abnormal hormonal milieu (Delporte et al., 2002; Halleux et al., 2001), together with the enhanced oxidative stress (Furukawa et al., 2004) and the pro-inflammatory state (Bruun et al., 2003) that exist in obesity and the metabolic syndrome.  

- AT apelin and plasma levels increased in obesity (Heinonen et al., 2005). Conversely, both circulating apelin and its expression in AT were reduced after weight loss consecutive to a hypocaloric diet in obese women (Castan-Laurell et al., 2008). Its mRNA expression was similar in adipocytes and stromal-vascular cells (SVC) isolated from human subcutaneous (sc) tissue and there was no difference in adipocyte apelin expression in intra-abdominal and sc fat pads in mice (Boucher et al., 2008). Conversely, ApN may reduce plasma levels of leptin (Arita et al., 1999; Brichard et al., 2003) and decrease in obese subjects, in type 2 diabetes or cardiovascular disease (CVD) (Ouchi and Walsh, 2007). This sub-regulation may involve the abnormal hormonal milieu (Delporte et al., 2002; Halleux et al., 2001), together with the enhanced oxidative stress (Furukawa et al., 2004) and the pro-inflammatory state (Bruun et al., 2003) that exist in obesity and the metabolic syndrome.  

- Possible relations between circulating visfatin and anthropometric or metabolic parameters in obesity and type 2 diabetes have been found in some but not all studies (Garten et al., 2009; Rasouli and Kern, 2008); the contradictory findings may be due in part to considerable differences in visfatin immunoassays (Garten et al., 2009; Imai, 2009).  

| Receptors & effects | Leptin from the periphery is transported into the brain, combines with its receptor b in the hypothalamus, and stimulates JAK-STAT3, leading to repression of "orexigenic peptides" (e.g., AdipoR1 and AdipoR2 serve as main receptors for ApN in vivo and belong to a new family of receptors (seven transmembrane domains) but to be structurally and functionally closely related to the adiponectin receptor).  

- It promising target in the management of insulin resistance (Cekmez et al., 2011).  

- It has vital roles in insulin sensitivity (Cekmez et al., 2011).
neuropeptide Y and agouti-related protein), and increase in "anorexigenic peptides" (e.g., proopiomelanocortin and corticotrophin-releasing hormone) (Ahima, 2008), in that way curtailing food intake. In the ordinary form of obesity, resistance to leptin has been ascribed to reduced transport of leptin across the blood–brain barrier (BBB) and to increased hypothalamic levels of SOCS3 and endoplasmic reticulum (ER) stress, which inhibit leptin signaling (Flier, 1998; Morton et al., 2005; Ozcan et al., 2009). Notably, low leptin levels stimulate overfeeding and repress energy expenditure, thyroid and reproductive hormones, and immunity (Maury and Brichard, 2010). Anorexigenic peptides such as proopiomelanocortin and corticotrophin-releasing hormone functionally distinct from G-protein coupled receptors (Maury and Brichard, 2010).

AdipoR1 is expressed in muscle, while AdipoR2 is expressed in liver (Yamauchi et al., 2003). AdipoR1 is more tightly associated to the activation of AMPK pathways that adjust the inhibition of gluconeogenesis together with increased fatty acid oxidation, while AdipoR2 is more concerned with the activation of the PPAR-α pathways, which stimulate energy dissipation by increasing fatty acid oxidation and reduce oxidative stress and inflammation (Capeau, 2007; Yamauchi et al., 2007). Interaction of an adaptor protein, APPL1 with AdipoR1 appears to play significant roles in ApN signaling (Mao et al., 2006). After binding, ApN showed insulin-sensitizing and fat-burning effects suggestive of those of leptin, but possesses anti-atherogenic, anti-inflammatory and anti-oxidant properties as well, thereby thwarting simultaneously several facets of the metabolic syndrome (Kadowaki and Yamauchi, 2005; Takemura et al., 2007).

Table 3. Summary about the different states of adiponectinae

<table>
<thead>
<tr>
<th>Compare face</th>
<th>hypoadiponectinaemia</th>
<th>hyperadiponectinaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Causes</strong></td>
<td>Raised levels of these endogenous cytokines, particularly several pro-inflammatory cytokines such as IL-6, IL-8 and TNF-α (Engeli et al., 2003) may be directly responsible for the inhibition of adiponectin secretion (Bruun et al., 2001; German et al., 2010).</td>
<td>Loss of insulin receptor (dysfunction) could be construed as a compensatory response of the adipose tissue that exerts insulin-sensitising effects on remote tissues (Semple et al., 2006 &amp; 2007).</td>
</tr>
<tr>
<td><strong>Rodent studies</strong></td>
<td>In experimental models, adiponectin has been reported to have anti-inflammatory effects against liver injury (Lago et al., 2007). Adiponectin administration recovers liver function in both alcoholic and non-alcoholic fatty liver disease as the result of TNF suppression, and in mice it reduces liver enzyme levels, hepatomegaly and steatosis (Xu et al., 2003), attenuates liver fibrosis (Kamada et al., 2003), and protects against LPS-induced liver injury (Masaki et al., 2004).</td>
<td>In mice, expressing the insulin receptor only in adipose tissue, brain and pancreatic beta cells, increased adiponectin coexists with adiponectin resistance, as obvious by blunted ability of adiponectin to lower blood glucose and stimulate hepatic AMP-dependent kinase phosphorylation (Lin et al., 2007).</td>
</tr>
</tbody>
</table>
In humans, hypoadiponectinemia has been linked to inflammatory atherosclerosis (Funahashi et al., 1999), and they are associated with increased vascular smooth cell proliferation in response to injury, increased free fatty acid levels, and insulin resistance (Pischon et al., 2004). The conjunction of pro-diabetic and proatherogenic effects of reduced adiponectin levels, as observed in metabolic syndrome, makes adiponectin a bridge between obesity and inflammation (Lago et al., 2007). Also, plasma adiponectin levels are reduced in subjects with obesity and insulin resistance or type 2 diabetes mellitus, and are inversely correlated with visfatin and fasting insulin levels (Weyer et al., 2001; Punthakee et al., 2006; Cekmez et al., 2011).

In most cases, blood adiponectin concentrations correlate with insulin sensitivity, and yet in patients with severe insulin resistance due to loss of insulin receptor function (Groeneveld et al., 2012). This mechanism remains to be fully established.

**Table 4. Pro-inflammatory cytokines and chemokines during obesity**

<table>
<thead>
<tr>
<th>Compare face</th>
<th>Tumor necrosis factor-alpha (TNF-α)</th>
<th>Monocyte chemoattractant protein-1 (MCP-1)</th>
<th>Interleukin-6 (IL-6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nature</td>
<td>- It is an immunomodulatory and pro-inflammatory cytokine that is synthesized as a 26 kDa transmembrane protein that undergoes cleavage by metalloproteinases and is released into the circulation as a soluble molecule (Kriegler et al., 1988; Zhuang et al., 2009).</td>
<td>- It is a chemokine (C-C motif), member of the small inducible cytokine family and ligand 2 (CCL-2) (Kim et al., 2006; Goossens, 2008).</td>
<td>- It is a cytokine produced by several cells (fibroblasts, endothelial cells, monocytes, adipocytes, etc) (Bastard et al., 2007).</td>
</tr>
<tr>
<td>Secretion</td>
<td>- It is produced in the stroma of fat tissue, mainly in macrophage (Bogan and Lodish, 1999; Weisberg et al., 2003; Winkler et al., 2003; Park et al., 2005; Cao et al., 2008). Also, it is also more expressed in visceral than in subcutaneous fat (Fain et al., 2004; Einstein et al., 2005; Cao et al., 2008; Maury et al., 2009).</td>
<td>- It is produced by macrophages, endothelial cells and adipocytes (Gerhardt et al., 2001; Christiansen et al., 2005). It is more expressed in stromal-vascular cells than in adipocytes and in visceral adipose tissue than in subcutaneous adipose tissue (Bruun et al., 2005).</td>
<td>- Omental adipose tissue produces more IL-6 than abdominal subcutaneous adipose tissue, and IL-6 released from isolated omental adipocytes in humans was significantly greater than that released from subcutaneous adipocytes (Zhuang et al., 2009).</td>
</tr>
<tr>
<td>Functions &amp; effects</td>
<td>- The effects of TNF-α on adipocytes include inhibition of lipogenesis, elevated lipolysis, increased leptin secretion, decreased adiponectin secretion, reduced glucose transporter-4 expression, and impaired insulin signaling (Moller, 2000; Trujillo et al., 2006).</td>
<td>- It is a potent chemoattractant playing a role in the recruitment of monocytes/macrophages (macrophage infiltration) into the adipose tissue and lymphocyte recruitment to sites of injury and infection (Baggiolini, 1998; Maury and Brichard, 2010).</td>
<td>- It not only acts in paracrine/autocrine pathway but also acts through endocrine and CNS pathways to reduce the extension of fat tissue.</td>
</tr>
<tr>
<td></td>
<td>- In general, TNF-α also plays important role in the development of atherosclerosis through its involvement in monocyte migration, in monocyte-macrophage conversion, at the endothelial cell wall via nuclear</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Human studies

**Table 4. Pro-inflammatory cytokines and chemokines during obesity**

<table>
<thead>
<tr>
<th>Compare face</th>
<th>Tumor necrosis factor-alpha (TNF-α)</th>
<th>Monocyte chemoattractant protein-1 (MCP-1)</th>
<th>Interleukin-6 (IL-6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nature</td>
<td>- It is an immunomodulatory and pro-inflammatory cytokine that is synthesized as a 26 kDa transmembrane protein that undergoes cleavage by metalloproteinases and is released into the circulation as a soluble molecule (Kriegler et al., 1988; Zhuang et al., 2009).</td>
<td>- It is a chemokine (C-C motif), member of the small inducible cytokine family and ligand 2 (CCL-2) (Kim et al., 2006; Goossens, 2008).</td>
<td>- It is a cytokine produced by several cells (fibroblasts, endothelial cells, monocytes, adipocytes, etc) (Bastard et al., 2007).</td>
</tr>
<tr>
<td>Secretion</td>
<td>- It is produced in the stroma of fat tissue, mainly in macrophage (Bogan and Lodish, 1999; Weisberg et al., 2003; Winkler et al., 2003; Park et al., 2005; Cao et al., 2008). Also, it is also more expressed in visceral than in subcutaneous fat (Fain et al., 2004; Einstein et al., 2005; Cao et al., 2008; Maury et al., 2009).</td>
<td>- It is produced by macrophages, endothelial cells and adipocytes (Gerhardt et al., 2001; Christiansen et al., 2005). It is more expressed in stromal-vascular cells than in adipocytes and in visceral adipose tissue than in subcutaneous adipose tissue (Bruun et al., 2005).</td>
<td>- Omental adipose tissue produces more IL-6 than abdominal subcutaneous adipose tissue, and IL-6 released from isolated omental adipocytes in humans was significantly greater than that released from subcutaneous adipocytes (Zhuang et al., 2009).</td>
</tr>
<tr>
<td>Functions &amp; effects</td>
<td>- The effects of TNF-α on adipocytes include inhibition of lipogenesis, elevated lipolysis, increased leptin secretion, decreased adiponectin secretion, reduced glucose transporter-4 expression, and impaired insulin signaling (Moller, 2000; Trujillo et al., 2006).</td>
<td>- It is a potent chemoattractant playing a role in the recruitment of monocytes/macrophages (macrophage infiltration) into the adipose tissue and lymphocyte recruitment to sites of injury and infection (Baggiolini, 1998; Maury and Brichard, 2010).</td>
<td>- It not only acts in paracrine/autocrine pathway but also acts through endocrine and CNS pathways to reduce the extension of fat tissue.</td>
</tr>
<tr>
<td></td>
<td>- In general, TNF-α also plays important role in the development of atherosclerosis through its involvement in monocyte migration, in monocyte-macrophage conversion, at the endothelial cell wall via nuclear</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
factor kappa-light-chain-enhancer of activated B-cells (NF-κB) activation, and in inflammatory changes in the vascular wall (Fonseca-Alaniz et al., 2007).

- It is overexpressed in adipose tissue of obese individuals (Maury et al., 2009) and falls after weight loss (Dandona et al., 1998). Its elevation can reduce visceral fat volume (Maury and Brichard, 2010).

- Circulating and adipose tissue levels of MCP-1 are elevated in obese (Bruun et al., 2005) rodents (Sartipy and Loskutoff, 2003; Takahashi et al., 2003) and individuals (Nomura et al., 2000; Piemonti et al., 2003), and their levels have been found to decrease after weight loss (Schernthaner et al., 2006).

- Plasma IL6 levels are elevated in obesity and in T2DM and are positively associated with plasma FFA levels and with body mass (Lazar, 2005; Urs et al., 2004; Bastard et al., 2007) where this can reduce visceral fat volume (Maury and Brichard, 2010).

### Activity & expression in obesity & T2DM

- Alter insulin synthesis & secretion
- Alter glucagon synthesis
- Alter hepatic glucose output
- Alter FFA metabolism
- Alter lipogenesis
- May cause inflammation
- Alter insulin action
- Alter FFA metabolism
- Alter energy expenditure
- Alter triglyceride contents
- Alter angiogenesis
- May cause thrombosis, inflammation or oxidative stress
- Alter platelet aggregation
- Alter angiogenesis
- Alter chemotaxis of neutrophils & all immune functions

**Figure 1. General adipokines network**
Macronutrients → Obesity

From adipocyte:
- Decrease adiponectin & omentin
- Increase leptin, adipin, apelin, chemerin, visfatin, vaspin, RBP-4

From macrophage:
- Increase TNF-α, TGF-β, IL-6, IL-8, IL-10, IL-1β, MCP-1, chemokines
- Decrease anti-inflammatory adipokines (leptin, adiponectin & others)
- Increase pro-inflammatory adipokines (IL-8 & OTHERS)

Disturbance in adipokines secretions
- Increase fat deposition (non-esterified & free FA; hyperlipidaemia)
- Increase food intake, gluconeogenesis & ROS
- Decrease energy expenditure & glucose use
- Mitochondria damage & macrophage infiltration

Disturbance in all biological functions

Systemic inflammation

Cardiovascular dysfunction  Metabolic syndrome  Insulin resistance  Systemic DM2

Endothelial dysfunction:
- Decrease NO
- Increase superoxide

Cardiometabolic risk  Hyperglycaemia

- Increase insulin demand
- Impaired insulin secretion
β-cell failure

Figure 2. Adipokines & insulin resistance interactions
Obesity → Normal pregnancy (diabetogenic state; hyperinsulinemia) → Maternal adipocyte dysfunction → Disturbance in maternal adipokines → Maternal obesity → Transfer into fetus to cause Fetal impairments & dysorganogenesis → Fetal dysfunction (birth injury, cellular damage or growth arrest) → Maldevelopment in offspring (diseases or death) → Normal fetal development → Under control of adipokines

Figure 3. Adipokines, maternal obesity and development